Regulation of connexin43 expression and function by prostaglandin E2 (PGE2) and parathyroid hormone (PTH) in osteoblastic cells.
Connexin43 (Cx43) forms gap junctions that mediate intercellular communication between osteoblasts. We have examined the effects of prostaglandin E2 (PGE2) and parathyroid hormone (PTH) on gap junctional communication in the rat osteogenic sarcoma cells UMR 106-01. Incubation with either PGE2 or PTH rapidly (within 30 min) increased transfer of negatively charged dyes between UMR 106-01 cells. This stimulatory effect lasted for at least 4 h. Both PGE2 and PTH increased steady-state levels of Cx43 mRNA, but only after 2-4 h of incubation. Transfection with a Cx43 gene construct linked to luciferase showed that this effect of PTH was the result of transcriptional upregulation of Cx43 promoter. Stimulation of dye coupling and Cx43 gene transcription were reproduced by forskolin and 8Br-cAMP. Exposure to PGE2 for 30 min increased Cx43 abundance at appositional membranes in UMR 106-01, whereas total Cx43 protein levels increased only after 4-6 h of incubation with either PGE2 or PTH. Inhibition of protein synthesis by cycloheximide did not affect this early stimulation of dye coupling, but it significantly inhibited the sustained effect of PTH and forskolin on cell coupling. In summary, both PTH and PGE2, presumably through cAMP production, enhance gap junctional communication in osteoblastic cell cultures via two mechanisms: initial rapid redistribution of Cx43 to the cell membrane, and later stimulation of Cx43 gene expression. Modulation of intercellular communication represents a novel mechanism by which osteotropic factors regulate the activity of bone forming cells.
Civitelli
R
R
Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, Missouri 63110, USA. rcivitel@imgate.wustl.edu
Ziambaras
K
K
Warlow
P M
PM
Lecanda
F
F
Nelson
T
T
Harley
J
J
Atal
N
N
Beyer
E C
EC
Steinberg
T H
TH
D000818:Animals; D002449:Cell Aggregation / Q000187:drug effects; D005576:Colforsin / Q000494:pharmacology; D018031:Connexin 43 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D000242:Cyclic AMP / Q000378:metabolism; D003609:Dactinomycin / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology*; D005452:Fluoresceins / Q000008:administration & dosage; D005456:Fluorescent Dyes / Q000008:administration & dosage; D005786:Gene Expression Regulation / Q000187:drug effects; D015151:Immunoblotting; D007546:Isoquinolines / Q000008:administration & dosage; D008845:Microinjections; D010006:Osteoblasts / Q000166:cytology / Q000502:physiology*; D010120:Oxytocics / Q000494:pharmacology*; D010281:Parathyroid Hormone / Q000494:pharmacology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D051381:Rats; D015398:Signal Transduction / Q000502:physiology; D013997:Time Factors; D014407:Tumor Cells, Cultured
D018031:Connexin 43; D005452:Fluoresceins; D005456:Fluorescent Dyes; D007546:Isoquinolines; D010120:Oxytocics; D010281:Parathyroid Hormone; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; D003609:Dactinomycin; D005576:Colforsin; C017475:lucifer yellow; D000242:Cyclic AMP; D015232:Dinoprostone; C007740:fluorexon